AUROBINDO PHARMA LTD vs LAURUS LABS LIMITED

A side-by-side comparison of AUROBINDO PHARMA LTD (AUROPHARMA) and LAURUS LABS LIMITED (LAURUSLABS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, AUROBINDO PHARMA LTD leads AUROPHARMA vs LAURUSLABS on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

25.41
P/E ratio
92.94
2.39
P/B ratio
15.32
0.25%
Dividend yield
0.13%
₹60.34
EPS
₹16.46

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

10.10%
Return on equity
18.30%
13.00%
Return on capital
18.00%
20.00%
EBITDA margin
26.00%
10.41%
Net margin
13.06%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.63%
Revenue CAGR (3Y)
4.09%
22.02%
Profit CAGR (3Y)
3.92%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹89,061 Cr
Market cap
₹82,511 Cr
₹33,653 Cr
Revenue
₹6,813 Cr
₹3,503 Cr
Net profit
₹890 Cr
0.21
Debt / equity
0.48
AUROBINDO PHARMA LTD
  • ["The company has delivered a poor sales growth of 6.32% over past five years.", "Company has a low return on equity of 10.8% over last 3 years.", "Company might be capitalizing the interest cost"]
LAURUS LABS LIMITED
  • + ["Company has been maintaining a healthy dividend payout of 19.0%"]
  • ["Stock is trading at 15.7 times its book value", "The company has delivered a poor sales growth of 7.19% over past five years.", "Company has a low return on equity of 10.1% over last 3 years.", "Company might be capitalizing the interest cost"]
AUROBINDO PHARMA LTD full analysis LAURUS LABS LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.